In a report released on January 18, Balaji Prasad from Barclays assigned a Buy rating to Zoetis (ZTS – Research Report), with a price target of $255.00. The company’s shares opened today at $190.11.
According to TipRanks, Prasad is a 3-star analyst with an average return of 1.4% and a 45.49% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Coherus Biosciences, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zoetis with a $226.14 average price target, a 18.95% upside from current levels. In a report released on January 16, Goldman Sachs also maintained a Buy rating on the stock with a $226.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Zoetis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.15 billion and a net profit of $596 million. In comparison, last year the company earned a revenue of $2 billion and had a net profit of $529 million
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zoetis (ZTS) Company Description:
Founded in 1952, New Jersey-based Zoetis, Inc. is the world’s largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.
Read More on ZTS:
